BIOMARKER EXPLAINER
pTau-217 Blood Test
This page explains what plasma pTau-217 is, how the test is used in Alzheimer's workups, and how to think about results in clinical context.
What This Test Measures
pTau-217 is a phosphorylated form of tau protein measured in blood plasma. Elevated pTau-217 levels are associated with Alzheimer's-related brain pathology and may help clinicians estimate whether amyloid/tau changes are likely present.
In clinical workflows, pTau-217 is typically used as part of a broader evaluation, not as a stand-alone diagnosis.
In Plain Language
What It Can Tell You
The test can help estimate whether Alzheimer's-type biomarker changes are likely.
What It Cannot Do Alone
It does not replace a full medical assessment, cognitive history, or clinician judgment.
How It's Usually Used
It helps guide next steps, such as additional evaluation, imaging, or specialist follow-up.
Current Lab Details (Neurocode)
- Specimen type: EDTA plasma (lavender-top tube)
- Method: single-molecule assay (Simoa-based, per lab description)
- Expected turnaround: 3 to 10 days
- Reference range listed by Neurocode: negative, intermediate, positive bands
- Status: laboratory developed test (LDT), not FDA-cleared/approved
For exact collection, handling, and current cutoffs, review the source page directly: Neurocode ALZpath plasma pTau-217 test details.
Important Note
Test details can change over time. Clinical decisions should rely on the ordering clinician and the most current laboratory documentation.
Ready to Move Forward?
If you are exploring early biomarker testing, begin the ordering process or review our science overview.